MDXH MDXHEALTH

Mdxhealth to Present at Upcoming Investor Conferences

Mdxhealth to Present at Upcoming Investor Conferences

       

Mdxhealth to Present at Upcoming Investor Conferences

IRVINE, CA, and HERSTAL, BELGIUM – May 15, 2024 () – Mdxhealth SA (Nasdaq: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the following investor conferences in June 2024.

William Blair 44th Annual Growth Stock Conference

Presentation: Wednesday, June 5, at 5:00pm ET

Webcast:

Jefferies Global Healthcare Conference

Presentation: Thursday, June 6, at 1:30pm ET

Webcast:

Live webcasts of the presentations will be accessible on the Investor page of mdxhealth’s website at . Replays will be available for up to 60 days following each event.

About mdxhealth®

Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

mdxhealth







 
LifeSci Advisors (IR & PR)

US:

 

NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 

Attachment



EN
15/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MDXHEALTH

Jacob Mekhael ... (+5)
  • Jacob Mekhael
  • Lynn Hautekeete
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thomas Couvreur

Morning Notes : ABN NA, AD NA, HOMI BB, MDXH BB, NN NA, SEQUA BB, ONWD...

: ABN NA, AD NA, HOMI BB, MDXH BB, NN NA, SEQUA BB, ONWD BB, MRUS US

 PRESS RELEASE

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Pos...

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 millionAdjusted EBITDA profitability of $1.4 million for Q2 Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquisition expected to accelerate revenue growt...

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Vranken
 PRESS RELEASE

Mdxhealth Appoints Michael Holder to Board of Directors and Announces...

Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and pr...

Thomas Vranken
  • Thomas Vranken

mdxhealth 1Q25 results emphasize tissue-based growth, adj. EBITDA on t...

mdxhealth reported 1Q25 results, showing $ 24.3m rev (+22% y/y), driven primarily by a 41% rise in tissue-based test volumes. Company is clearly prioritizing the opportunity in tissue-based with higher ASP and margins, as tandem Confirm/GPS is well received by urology practices and pathology labs. Gross margins made a resulting 3 ppt jump y/y to 63.8% while opex remained largely in line, leading to adj. EBITDA of $ -1.3m. Mgmt reiterated its FY25 revenue guidance of $ 108-110m and confirmed it i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch